0.395
Passage Bio Inc Borsa (PASG) Ultime notizie
Fierce Biotech Layoff Tracker 2025: Pliant cuts 45% of workforce; Arvinas lays off a third of staffers - Fierce Biotech
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):